Powerful beneficial effects of benfotiamine on cognitive impairment and -amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Reduction of glucose metabolism in brain is one of the main features of Alzheimer's disease. Thiamine (vitamin B1)-dependent processes are critical in glucose metabolism and have been found to be impaired in brains from patients with Alzheimer's disease. However, thiamine treatment exerts little beneficial effect in these patients. Here, we tested the effect of benfotiamine, a thiamine derivative with better bioavailability than thiamine, on cognitive impairment and pathology alterations in a mouse model of Alzheimer's disease, the amyloid precursor protein/presenilin-1 transgenic mouse. We show that after a chronic 8 week treatment, benfotiamine dose-dependently enhanced the spatial memory of amyloid precursor protein/presenilin-1 mice in the Morris water maze test. Furthermore, benfotiamine effectively reduced both amyloid plaque numbers and phosphorylated tau levels in cortical areas of the transgenic mice brains. Unexpectedly, these effects were not mimicked by another lipophilic thiamine derivative, fursultiamine, although both benfotiamine and fursultiamine were effective in increasing the levels of free thiamine in the brain. Most notably, benfotiamine, but not fursultiamine, significantly elevated the phosphorylation level of glycogen synthase kinase-3alpha and -3beta, and reduced their enzymatic activities in the amyloid precursor protein/presenilin-1 transgenic brain. Therefore, in the animal Alzheimer's disease model, benfotiamine appears to improve the cognitive function and reduce amyloid deposition via thiamine-independent mechanisms, which are likely to include the suppression of glycogen synthase kinase-3 activities. These results suggest that, unlike many other thiamine-related drugs, benfotiamine may be beneficial for clinical Alzheimer's disease treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277 · cited 2×
“Moreover, all of the mechanisms described for diabetic patholo- gies are specifically linked to abnormally high concentrations of blood glucose, reflecting a single hyperglycaemia-induced process of superoxide overproduction by the mitochondrial electron trans- port chain (Nishikawa et al., 2000).”
BackgroundCholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 2×
“Thus, Alzheimer’s disease has been considered to be an ‘insulin-resistant brain state’ or even a type 3 diabetes mellitus (Steen et al., 2005).”
BackgroundDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 2×
“Furthermore, type 2 diabetes mellitus, the most common metabolic disorder with a prevalence that increases with ageing just like Alzheimer’s disease, has been identified as a risk factor for Alzheimer’s disease (Arvanitakis et al., 2004).”
BackgroundIncreased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950 · cited 2×
“Conversely, patients with Alzheimer’s disease also have a higher risk of developing type 2 diabetes mellitus (Janson et al., 2004).”
BackgroundHammes, H.-P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., et al. (2003) · Nature Medicine · doi:10.1038/nm834 · Cited by 785 · cited 4×
“…glycation end product formation pathway and the diacylglycerol-protein kinase C pathway), as well as hyperglycaemia-associated nuclear factor-kB activation, by acti- vating transketolase, thus preventing the development and pro- gression of diabetic nerve complications (Hammes et al., 2003).”
BackgroundInfluentialPositron emission tomography imaging in dementia
HERHOLZ, K., CARTER, S. F., & JONES, M. (2007) · The British Journal of Radiology · doi:10.1259/bjr/97295129 · Cited by 287
Kennedy, A. M., Frackowiak, R. S. J., Newman, S. K., Bloomfield, P. M., Seaward, J., Roques, P., Lewington, G., Cunningham, V. J., & Rossor, M. N. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11270-7 · Cited by 250
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“One previous study found that BFT reduced phosphorylated tau levels, ameliorated Aβ load, and improved cognitive function in an AD mouse model APP/PS1 mice.(519) Another study treated P301S tau transgenic mice with chronically BMT dietary from the age of 1 to 10 months and found that BFT significantly decreased the ex…”
BackgroundChen, Z., & Zhong, C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.004 · Cited by 673
Self-citationVitamin B1 (thiamine) and dementia
Gibson, G. E., Hirsch, J. A., Fonzetti, P., Jordan, B. D., Cirio, R. T., & Elder, J. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13031 · Cited by 214
Benfotiamine Attenuates Inflammatory Response in LPS Stimulated BV-2 Microglia
Bozic, I., Savic, D., Laketa, D., Bjelobaba, I., Milenkovic, I., Pekovic, S., Nedeljkovic, N., & Lavrnja, I. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118372 · Cited by 101
“Benfotiamine significantly reduced the formation of amyloid plaques in APP/PS1 mice [31] and was able to attenuate the glucose-induced increase in β-amyloid protein synthesis in isolated HEK293 cells [32].”
BackgroundKidney, heart and brain: three organs targeted by ageing and glycation
Frimat, M., Daroux, M., Litke, R., Nevière, R., Tessier, F. J., & Boulanger, E. (2017) · Clinical Science · doi:10.1042/cs20160823 · Cited by 88
Metadata
- Authors
- Pan, X., Gong, N., Zhao, J., Yu, Z., Gu, F., Chen, J., Sun, X., Zhao, L., Yu, M., Xu, Z., Dong, W., Qin, Y., Fei, G., Zhong, C., & Xu, T. L.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-04-12
- Volume
- 133
- Issue
- 5
- Pages
- 1342-1351
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2145373866
- Cited by
- 134
- References
- 8
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Powerful beneficial effects of benfotiamine on cognitive impairment and -amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. https://app.cochat.ai/papers/10.1093/brain/awq069
- The paper
- Pan, X., Gong, N., Zhao, J., Yu, Z., Gu, F., Chen, J., Sun, X., Zhao, L., Yu, M., Xu, Z., Dong, W., Qin, Y., Fei, G., Zhong, C., & Xu, T. L. (2010). Powerful beneficial effects of benfotiamine on cognitive impairment and -amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain. https://doi.org/10.1093/brain/awq069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.